ADMAADMA Biologics, Inc.

$4B

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M+189.1% YoY

Gross Profit

-$7M-65.0% margin

Operating Income

-$17M-164.4% margin

Net Income

-$19M-188.7% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

-15.3%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$27M

Stock-Based Comp.

$676,548

Balance Sheet

Total Assets

$211M

Total Liabilities

$114M

Stockholders' Equity

$96M

Cash & Equivalents

$101M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$4M	+189.1%
Gross Profit	-$7M	-$6M	-12.8%
Operating Income	-$17M	-$13M	-27.0%
Net Income	-$19M	-$13M	-47.3%

Revenue Segments

ADMA BioManufacturing

$8M76%

Plasma Collection Centers

$2M24%

Corporate

$35,7080%

ADMA Q1 2020 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena